Stability of Multicomponent Antidote Parenteral Formulations for Autoinjectors against Chemical War Agents (Neurotoxics) [PDF]
PharmaceuticsCombinations of different drugs are formulated in autoinjectors for parenteral administration against neurotoxic war agents. In this work, the effects on the chemical stability of the following three variables were studied: (i) type of drug combination ...
María José Rodríguez Fernández +4 more
doaj +2 more sources
Transitioning from Oxime to the Next Potential Organophosphorus Poisoning Therapy Using Enzymes
Journal of Chemistry, 2021 For years, organophosphorus poisoning has been a major concern of health problems throughout the world. An estimated 200,000 acute pesticide poisoning deaths occur each year, many in developing countries.
Rauda A. Mohamed +7 more
doaj +2 more sources
A Comparison of the Neuroprotective Efficacy of Newly Developed Oximes (K156, K203) and Currently Available Oximes (Obidoxime, HI-6) in Cyclosarin-poisoned Rats [PDF]
Acta Medica, 2008 The neuroprotective effects of newly developed oximes (K156, K203) and currently available oximes (obidoxime, HI-6) in combination with atropine in rats poisoned with cyclosarin were studied.
Jiří Kassa +4 more
doaj +2 more sources
Nanoparticulate transport of oximes over an in vitro blood-brain barrier model. [PDF]
PLoS ONE, 2010 BACKGROUND: Due to the use of organophosphates (OP) as pesticides and the availability of OP-type nerve agents, an effective medical treatment for OP poisonings is still a challenging problem.
Sylvia Wagner +9 more
doaj +6 more sources
Molecular modeling studies on the interactions of 7-methoxytacrine-4-pyridinealdoxime, 4-PA, 2-PAM, and obidoxime with VX-inhibited human acetylcholinesterase: a near attack conformation approach [PDF]
Journal of Enzyme Inhibition and Medicinal Chemistry, 2019 7-methoxytacrine-4-pyridinealdoxime (7-MEOTA-4-PA, named hybrid 5C) is a compound formerly synthesized and evaluated in vitro, together with 4-pyridine aldoxime (4-PA) and commercial reactivators of acetylcholinesterase (AChE). This compound was designed
Jorge Alberto Valle da Silva +4 more
doaj +2 more sources
The Organophosphate Paraoxon and Its Antidote Obidoxime Inhibit Thrombin Activity and Affect Coagulation In Vitro. [PDF]
PLoS ONE, 2016 Organophosphates (OPs) are potentially able to affect serine proteases by reacting with their active site. The potential effects of OPs on coagulation factors such as thrombin and on coagulation tests have been only partially characterized and potential ...
Valery Golderman +8 more
doaj +1 more source
Pd(II) complexes of acetylcholinesterase reactivator obidoxime [PDF]
Interdisciplinary Toxicology, 2014 ABSTRACT The ability of the acetylcholinesterase reactivator obidoxime (H2L2+) to bind palladium(II) cations was evaluated spectrophotometrically at different reaction conditions (pH, reaction time, metal-to-ligand molar ratio). The results showed that immediately after mixing the reagents, pH 7.4, complex species of composition [PdHL]3+
Nedzhib, Ahmed +4 more
openaire +2 more sources
Pro: Oximes should be used routinely in organophosphate poisoning
British Journal of Clinical Pharmacology, Volume 88, Issue 12, Page 5064-5069, December 2022., 2022 In poisoning with organophosphorus compounds (OP), patients can only profit from the regeneration of acetylcholinesterase, when the poison load has dropped below a toxic level. Every measure that allows an increase of synaptic acetylcholinesterase (AChE) activity at the earliest is essential for timely termination of the cholinergic crisis.
Horst Thiermann, Franz Worek
wiley +1 more source
Archiv der Pharmazie, Volume 355, Issue 11, November 2022., 2022 Significant effort has been invested into the development of cholinesterase reactivators that are capable of treating organophosphorus poisoning. A series of 12 coumarin derivatives equipped with linker‐connected nonaromatic terminal amino moieties were prepared in this study.
Paul W. Elsinghorst +6 more
wiley +1 more source
Advanced Therapeutics, Volume 4, Issue 1, January 2021., 2021 Targeting of the brain has been achieved by apolipoprotein E‐functionalization of drug‐loaded polymeric nanoparticles via different approaches to treat central nervous system (CNS) diseases such as Alzheimer's disease or cerebral cancer. After in vitro and in vivo evaluation, nanoparticle recognition by low density lipoprotein‐receptors and crossing of
Natascha Hartl +2 more
wiley +1 more source